3 new first-in-class therapies coming
See how innovation is driving the latest product development.
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: April 2023
2023 will be a busy year for new pharmaceutical treatments.
Welcome to the next issue of Drugs to Watch for 2023
In this Drug Pipeline Insights Report, we review:
- Two respiratory syncytial virus (RSV) vaccines
- A gene therapy for Duchenne muscular dystrophy (DMD)
- First FDA-approved treatment for nonalcoholic steatohepatitis (NASH), a rare liver disease
Don't want to read the full report? Download the brief summary.
Related Content
4 new drugs to watch this year
Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.
Which rules will impact pharmacy in 2023?
2023 is already a busy year for pharmacy regulation. Read about the latest regulations that could impact you and your pharmacy benefit plan.
3 new drugs to watch this fall
As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.